Drugs / IDOV-Immune
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07656090 | Dec 2025 → Oct 2027 expected | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Enrolling by invitation | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06910657 | Aug 2025 → Jan 2027 expected | adrenal gland neoplasm, breast cancer, cervical cancer, colorectal cancer +12 | ViroMissile, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | ViroMissile, Inc. | Regulatory ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance viromissile.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-02-17 | ViroMissile, Inc. | ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance viromissile.com ↗ |
| 2025-12-11 | ViroMissile, Inc. | ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors viromissile.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDOV-Immune | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07656090 ↗ |
| Route | Intravenous | “Participants will receive a single intravenous (IV) infusion of IDOV-Immune” NCT06910657 ↗ |